Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma

Background: Human papilloma virus (HPV) infection is a powerful prognostic biomarker in head and neck squamous cell carcinoma (HNSCC). Increased epidermal growth factor receptor (EGFR) gene copy number and protein expression have been reported to be negative predictors of outcome. This study examined the relationship between HPV status, EGFR gene copy number, EGFR protein expression, and clinical outcome in HNSCC patients treated with chemoradiation. Methods: HPV status was determined using p16INK4A immunohistochemistry (IHC), EGFR gene copy number was evaluated with FISH, and EGFR protein expression by IHC in 212 subjects. Results:EGFR FISH was positive in 41 of 204 (20%) patients and was negatively correlated with failure-free survival (FFS; HR = 1.84, P = 0.027) and overall survival (OS; HR = 1.78, P = 0.082). For p16INK4A, 85 of 200 (42.5%) patients were found to be p16 positive, including 75 of 131 (57%) with oropharyngeal cancer. Patients with p16-positive oropharyngeal cancer had significantly improved FFS (HR = 0.28, P < 0.001) and OS (HR = 0.31, P = 0.002). Only 2 of 126 (1.6%) oropharyngeal cancer patients were found to be p16+/EGFR FISH+. EGFR IHC was positive in 81 of 93 (87%) of patients and was associated with poorer FFS (HR = 1.98, P = 0.35) and OS (HR = 2.52, P = 0.22). Conclusions: Increased EGFR gene copy number is largely restricted to p16INK4A-negative oropharyngeal cancer. Although p16INK4A and EGFR FISH are both predictive of outcome in univariate analyses, only p16INK4A remains independently predictive. Impact: Knowledge of HPV and EGFR status can have implications for treatment options and prognosis in HNSCC. Cancer Epidemiol Biomarkers Prev; 20(6); 1230–7. ©2011 AACR.

[1]  André Raspaud,et al.  On backbone coloring of graphs , 2012, J. Comb. Optim..

[2]  K. Ang,et al.  Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. , 2011, International journal of radiation oncology, biology, physics.

[3]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[4]  R. Fisher,et al.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Thorstad,et al.  p16 Positive Oropharyngeal Squamous Cell Carcinoma:An Entity With a Favorable Prognosis Regardless of Tumor HPV Status , 2010, The American journal of surgical pathology.

[6]  Gypsyamber D'Souza,et al.  HPV-associated head and neck cancer: a virus-related cancer epidemic. , 2010, The Lancet. Oncology.

[7]  Jonathan R. Clark,et al.  Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. , 2010, European journal of cancer.

[8]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[9]  S. Lippman,et al.  Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) , 2010, Head & neck oncology.

[10]  R. Fisher,et al.  Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Meyer,et al.  Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. , 2010, Oral oncology.

[12]  L. Terracciano,et al.  Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? , 2009, International journal of cancer.

[13]  S. Fox,et al.  Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial , 2010 .

[14]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[15]  C. R. Leemans,et al.  Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. , 2009, European journal of cancer.

[16]  Christine H Chung,et al.  Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications , 2009, Clinical Cancer Research.

[17]  F. Cappuzzo,et al.  EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer , 2009, Journal of Clinical Pathology.

[18]  Martin Görner,et al.  HPV & head and neck cancer: a descriptive update , 2009, Head & neck oncology.

[19]  Jonathan R. Clark,et al.  Prognostic Significance of Vascular Endothelial Growth Factor in Squamous Cell Carcinomas of the Tonsil in Relation to Human Papillomavirus Status and Epidermal Growth Factor Receptor , 2009, Annals of Surgical Oncology.

[20]  T. Ried,et al.  EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. , 2009, European journal of cancer.

[21]  Albert C. Koong,et al.  The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. , 2009, International journal of radiation oncology, biology, physics.

[22]  A. Russo,et al.  HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  L. Terracciano,et al.  Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. , 2008, Human pathology.

[24]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[25]  C. Tsien,et al.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Westra,et al.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.

[27]  Jeremy MG Taylor,et al.  Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. , 2007, International journal of radiation oncology, biology, physics.

[28]  Diane D. Liu,et al.  Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Dienes,et al.  Combined analysis of HPV‐DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer , 2007, International journal of cancer.

[30]  E. Choi,et al.  HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c‐myc during tumor formation , 2007, International journal of cancer.

[31]  M. Pierotti,et al.  Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[32]  Christine H Chung,et al.  Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Kodet,et al.  Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. , 2005, Neoplasma.

[35]  R. Fisher,et al.  Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[37]  R. Fisher,et al.  Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[39]  R. Day,et al.  Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. , 1998, Journal of the National Cancer Institute.